Literature DB >> 33204001

Long non-coding RNA FOXD3-AS1 silencing exerts tumor suppressive effects in nasopharyngeal carcinoma by downregulating FOXD3 expression via microRNA-185-3p upregulation.

Jiang Hu1, Jun Pan2, Zhiguo Luo3, Qiwen Duan3, Dan Wang3.   

Abstract

Emerging evidence indicates that the incidence of nasopharyngeal carcinoma (NPC) remains high in endemic regions despite changing environmental factors, suggesting that genetic traits contribute to its development. Recently, long non-coding RNA-microRNA-messenger RNA (lncRNA-miRNA-mRNA) axis has been reported to be implicated in the pathophysiological processes of malignancies. Moreover, initial bioinformatic analysis revealed a highly expressed lncRNA Forkhead box D3 antisense RNA1 (FOXD3-AS1) for mechanistic network underlying NPC in this present study. Therefore, this study aims to delineate the ability of lncRNA FOXD3-AS1 to influence the NPC progression. The relationship among lncRNA FOXD3-AS1, miR-185-3p, and FOXD3 was identified with bioinformatics prediction, dual-luciferase reporter gene assays, RNA-binding protein immunoprecipitation, and RNA pull-down assays. Furthermore, effects of lncRNA FOXD3-AS1 on malignant phenotypes in vitro, alongside tumor formation in vivo, of transfected NPC stem-like cells were examined with gain- and loss-of-function experiments. Our findings revealed that lncRNA FOXD3-AS1 and FOXD3 exhibited increased expression levels, while miR-185-3p exhibited diminished levels in NPC. The levels of lncRNA FOXD3-AS1 and FOXD3 were further correlated with tumor node metastasis stage and pathological type of patients with NPC. LncRNA FOXD3-AS1 was also confirmed to negatively regulate the miR-185-3p expression, which further targeted the downstream gene FOXD3. In addition, lncRNA FOXD3-AS1 knockdown repressed cell stemness, colony formation, viability, invasion, migration, and in vivo tumor growth, and accelerated cell apoptosis. Moreover, FOXD3 silencing or miR-185-3p overexpression reversed the effects of lncRNA FOXD3-AS1. Our findings provide evidence indicating that lncRNA FOXD3-AS1 could bind to miR-185-3p to upregulate the FOXD3 expression, thereby promoting the development of NPC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33204001     DOI: 10.1038/s41417-020-00242-z

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  1 in total

1.  Down-regulation of long non-coding RNA FOXD3 antisense RNA 1 (FOXD3-AS1) inhibits cell proliferation, migration, and invasion in malignant glioma cells.

Authors:  Zhen-Hua Chen; Hong-Kang Hu; Chen-Ran Zhang; Cheng-Yin Lu; Yi Bao; Zheng Cai; Yong-Xiang Zou; Guo-Han Hu; Lei Jiang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

  1 in total
  5 in total

1.  LncRNA FOXD3-AS1 Promotes the Malignant Progression of Nasopharyngeal Carcinoma Through Enhancing the Transcription of YBX1 by H3K27Ac Modification.

Authors:  Huiyun Yang; Yuliang Pan; Jun Zhang; Long Jin; Xi Zhang
Journal:  Front Oncol       Date:  2021-07-29       Impact factor: 6.244

Review 2.  An Overview of Long Non-Coding (lnc)RNAs in Neuroblastoma.

Authors:  Francesca Baldini; Matilde Calderoni; Laura Vergani; Paola Modesto; Tullio Florio; Aldo Pagano
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

Review 3.  Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases.

Authors:  Qinfan Yao; Xiuyuan Zhang; Dajin Chen
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

4.  Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification.

Authors:  Xiaofeng Liu; Wenyan Chen; Yu Qi; Yongqian Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-14       Impact factor: 2.650

Review 5.  Insight into LncRNA- and CircRNA-Mediated CeRNAs: Regulatory Network and Implications in Nasopharyngeal Carcinoma-A Narrative Literature Review.

Authors:  Senmiao Zhang; Yanling Li; Shuyu Xin; Li Yang; Mingjuan Jiang; Yujie Xin; Yiwei Wang; Jing Yang; Jianhong Lu
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.